#ASCO21: AstraZeneca's PD-L1 Imfinzi tacks on 5-year survival data in NSCLC, which it's calling 'unprecedented'
Amid a sea of competitors in PD-(L)1, AstraZeneca has looked to outrun the big dogs in Merck and Bristol Myers Squibb with its Imfinzi. One way to differentiate? Long-term effect — and now AstraZeneca has five-year data in NSCLC it thinks can set its drug apart.
Imfinzi posted an overall survival rate of 43% for Stage III non-small cell lung cancer patients whose tumors can’t be removed five years after chemoradiation treatment, according to data from the Phase III PACIFIC study set to be released at this weekend’s #ASCO21.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.